IHH Healthcare Withdraws IPO Plans for Indian Lab
By Ying Xian Wong
Malaysian hospital operator IHH Healthcare and other investors will withdraw plans for an initial public offering of Agilus Diagnostics in India, citing commercial considerations.
IHH said in a filing to the Malaysian bourse Wednesday that the IPO would be scrapped, which comes after it held talks with private-equity investors, indirect subsidiary Fortis Healthcare and Agilus. It added that Agilus, a unit of Fortis, could refile for an IPO in the future.
IHH didn't elaborate on the commercial reasons for the decision. It said the private-equity investors included the International Finance Corporation, NYLIM Jacob Ballas India Fund III and Resurgence PE Investments. Fortis had acted as promoter.
Agilus filed an IPO prospectus last September. The Gurgaon-based company operates a pathology laboratory network in India.
Write to Ying Xian Wong at yingxian.wong@wsj.com
(END) Dow Jones Newswires
February 14, 2024 01:14 ET (06:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?